rs1555535032
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001042492.3(NF1):c.6852_6855del(p.Tyr2285ThrfsTer5) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,460,962 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.0 ( 0 hom., cov: 32)
Exomes 𝑓: 6.8e-7 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
NF1
NM_001042492.3 frameshift
NM_001042492.3 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 8.62
Genes affected
NF1 (HGNC:7765): (neurofibromin 1) This gene product appears to function as a negative regulator of the ras signal transduction pathway. Mutations in this gene have been linked to neurofibromatosis type 1, juvenile myelomonocytic leukemia and Watson syndrome. The mRNA for this gene is subject to RNA editing (CGA>UGA->Arg1306Term) resulting in premature translation termination. Alternatively spliced transcript variants encoding different isoforms have also been described for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
?
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
?
Very rare variant in population databases, with high coverage;
PP5
?
Variant 17-31338733-CACTT-C is Pathogenic according to our data. Variant chr17-31338733-CACTT-C is described in ClinVar as [Pathogenic]. Clinvar id is 216866.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr17-31338733-CACTT-C is described in Lovd as [Pathogenic]. Variant chr17-31338733-CACTT-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
NF1 | NM_001042492.3 | c.6852_6855del | p.Tyr2285ThrfsTer5 | frameshift_variant | 46/58 | ENST00000358273.9 | |
NF1 | NM_000267.3 | c.6789_6792del | p.Tyr2264ThrfsTer5 | frameshift_variant | 45/57 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
NF1 | ENST00000358273.9 | c.6852_6855del | p.Tyr2285ThrfsTer5 | frameshift_variant | 46/58 | 1 | NM_001042492.3 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.00 AC: 0AN: 152128Hom.: 0 Cov.: 32 FAILED QC
GnomAD3 genomes
?
AF:
AC:
0
AN:
152128
Hom.:
Cov.:
32
FAILED QC
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1460962Hom.: 0 AF XY: 0.00000138 AC XY: 1AN XY: 726830
GnomAD4 exome
AF:
AC:
1
AN:
1460962
Hom.:
AF XY:
AC XY:
1
AN XY:
726830
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? Data not reliable, filtered out with message: AC0;AS_VQSR AF: 0.00 AC: 0AN: 152128Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74306
GnomAD4 genome
?
Data not reliable, filtered out with message: AC0;AS_VQSR
AF:
AC:
0
AN:
152128
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74306
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:16
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Neurofibromatosis, type 1 Pathogenic:8
Pathogenic, criteria provided, single submitter | research | Department of Research and Development, Institute Hermes Pardini | Feb 02, 2016 | PVS1 - disrupt gene (frameshift), PM2 - Absent in population databases, PM4 - Protein lenght change, PP3 - Multiple deleterious effect and PP4 - Patient's phenotype - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Mar 15, 2022 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Biochemical Molecular Genetic Laboratory, King Abdulaziz Medical City | Feb 05, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jan 28, 2024 | This sequence change creates a premature translational stop signal (p.Tyr2264Thrfs*5) in the NF1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with neurofibromatosis type 1 and with neurofibromatosis-Noonan syndrome (PMID: 7607663, 16835897, 24357598, 25325900). This variant is also known as c.6850_6853delACTT. ClinVar contains an entry for this variant (Variation ID: 216866). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | The observed frameshift variant c.6852_6855del (p.Tyr2285ThrfsTer5) in NF1 gene has been reported previously in multiple individuals affected with Neurofibromatosis Type 1 (Maruoka et al. 2014; Riva et al. 2022). The p.Tyr2285ThrfsTer5 variant is absent in gnomAD Exomes database. This variant has been submitted to the ClinVar database as Pathogenic (multiple submissions). This variant causes a frameshift starting with codon Tyrosine 2285, changes this amino acid to Threonine residue, and creates a premature Stop codon at position 5 of the new reading frame, denoted p.Tyr2285ThrfsTer5. This variant is predicted to cause loss of normal protein function through protein truncation. Loss of function variants in NF1 gene have been previously reported to be disease causing. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | Oct 26, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Aug 07, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Medical Genetics, University of Parma | Dec 20, 2019 | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jul 22, 2022 | This variant is expected to result in the loss of a functional protein. This variant was not reported in large, multi-ethnic, general populations (http://gnomad.broadinstitute.org). This variant has been identified in multiple unrelated individuals with clinical features of NF1, including at least one apparent de novo. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 03, 2022 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 24357598, 30530636, 31371350, 16835897, 7607663, 16944272, 19738042, 27980226, 25325900, 31776437, 34427956) - |
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jul 22, 2022 | This variant alters the translational reading frame of the NF1 mRNA and causes the premature termination of NF1 protein synthesis. In addition, this variant has been reported in individuals affected with neurofibromatosis and in a family with neurofibromatosis-Noonan syndrome in the published literature (PMIDs: 19738042 (2009), 7607663 (1995), 16835897 (2006), 25325900 (2014), 27980226 (2017) and 24357598 (2014)). Based on the available information, this variant is classified as pathogenic. - |
not specified Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | May 03, 2019 | The NF1 c.6852_6855delTTAC; p.Tyr2285fs variant (rs863224836), also known as c.6789_6792delTTAC for NM_000267.3, is reported in the literature in multiple individuals and families affected with neurofibromatosis type 1 (Banerjee 2017, Brems 2009, Griffiths 2007, Lee 2006, Robinson 1995), and a family affected with neurofibromatosis-Noonan syndrome (Ekvall 2014). This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 216866), and is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. This variant causes a frameshift by deleting 4 nucleotides, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: Banerjee S et al. Novel phenotypes of NF1 patients from unrelated Chinese families with tibial pseudarthrosis and anemia. Oncotarget. 2017 Jun 13;8(24):39695-39702. Brems H et al. Glomus tumors in neurofibromatosis type 1: genetic, functional, and clinical evidence of a novel association. Cancer Res. 2009 Sep 15;69(18):7393-401. Ekvall S et al. Novel association of neurofibromatosis type 1-causing mutations in families with neurofibromatosis-Noonan syndrome. Am J Med Genet A. 2014 Mar;164A(3):579-87. Griffiths S et al. Molecular diagnosis of neurofibromatosis type 1: 2 years experience. Fam Cancer. 2007;6(1):21-34. Lee MJ et al. Identification of forty-five novel and twenty-three known NF1 mutations in Chinese patients with neurofibromatosis type 1. Hum Mutat. 2006 Aug;27(8):832. Robinson PN et al. Two recurrent nonsense mutations and a 4 bp deletion in a quasi-symmetric element in exon 37 of the NF1 gene. Hum Genet. 1995 Jul;96(1):95-8. - |
Ganglioglioma Pathogenic:1
Likely pathogenic, no assertion criteria provided | research | Genome Sciences Centre, British Columbia Cancer Agency | May 21, 2019 | - - |
Juvenile myelomonocytic leukemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 23, 2024 | - - |
Neurofibromatosis-Noonan syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Oct 02, 2021 | Frameshift: predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant (PVS1_VS). The variant was observed as assumed (i.e. paternity and maternity not confirmed) de novoo (3billion dataset, PM6). It is not observed in the gnomAD v2.1.1 dataset (PM2). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 06, 2016 | Thec.6852_6855delTTACpathogenic mutation (also known as c.6789_6792delTTACand6789del-TTAC), located in codingexon46 of theNF1gene, results from a deletion of 4 nucleotides from positions 6852 to6855, causing a translationalframeshiftwith a predicted alternate stopcodon(p.Y2285Tfs*5). This pathogenic mutation has beenreported in severalindividuals whofulfilledNIH diagnostic criteria for NF1 (Robinson PN et al.HumGenet.1995;96(1):95-8, Griffiths S, et al.Fam. Cancer 2007 ; 6(1):21-34).In addition to the clinical data presented in the literature, sinceframeshiftsare typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMGRecommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007.Genet Med.2008;10:294). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at